Recent Updates — DARE
On September 28, 2026, Daré Bioscience, Inc. received a notice from Nasdaq indicating its common stock had traded below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has been granted an initial 180-day compliance period ending March 29, 2027, to restore the closing bid price to at least $1.00 for ten consecutive business days. Failure to comply may result in further review and potential delisting, though Daré retains the option to effect a reverse stock split if necessary to meet listing standards. The company operates in the biotechnology industry, developing therapeutic treatments.
On August 14, 2026, Dare Bioscience entered into a securities purchase agreement to sell 4,379,581 shares of common stock and pre-funded warrants at $1.37 per share in a registered direct offering. The company raised approximately $6.0 million in gross proceeds before expenses. Concurrently, the firm issued Series A and Series B warrants exercisable for up to 4,379,581 shares each at an exercise price of $1.37 per share. Proceeds will support working capital, general corporate purposes, and its 503B compounding and consumer health strategies. The closing is expected on August 17, 2026. Dare Bioscience operates in the biotechnology industry, focusing on women's health solutions.
Daré Bioscience reported financial results for the quarter ended June 30, 2026. The company generated total revenue of $0.2 million, driven by research and development services from Gates Foundation agreements, compared to negative revenue in the prior year period. Operating expenses were approximately $2.8 million, resulting in a net loss of $2.98 million. As of June 30, 2026, Daré held approximately $12.6 million in cash and cash equivalents with a working capital deficit of $0.2 million. Commercially, the company launched Flora Sync LF5 as its first direct-to-consumer product and is preparing for prescription dispensing of DARE to PLAY Sildenafil Cream in Q3 2026. The pipeline advanced with positive interim Phase 3 results for Ovaprene and initiation of a Phase 2 study for DARE-HPV, supported by $2.0 million in total NIH funding. Daré Bioscience is a biotech company focused on developing women's health products.